The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 2.8M data for 1.2M Compounds and 9.2K Targets. Of those, 1,332K data for 613K Compounds and 4.5K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

188 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Design and Discovery of N-(2-Methyl-5'-morpholino-6'-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3'-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers.EBI
Novartis Institutes For Biomedical Research
Design, synthesis, and biological evaluation of novel 4-anilinoquinazoline derivatives bearing amino acid moiety as potential EGFR kinase inhibitors.EBI
Xuzhou Medical University
Identification of a selective inhibitor of transforming growth factor▀-activated kinase 1 by biosensor-based screening of focused libraries.EBI
Chugai Pharmaceutical Co.
Design and synthesis of new RAF kinase-inhibiting antiproliferative quinoline derivatives. Part 2: Diarylurea derivatives.EBI
University Of Sharjah
Integrated bioinformatics, computational and experimental methods to discover novel Raf/extracellular-signal regulated kinase (ERK) dual inhibitors against breast cancer cells.EBI
Sichuan University
Pyridyl Isonicotinamide Inhibitors of RAF Kinase.EBI
Dart Neuroscience
Discovery of highly selective CRAF inhibitors, 3-carboxamido-2H-indazole-6-arylamide: In silico FBLD design, synthesis and evaluation.EBI
Hanyang University
Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2).EBI
Icahn School Of Medicine At Mount Sinai
Discovery of RAF265: A Potent mut-B-RAF Inhibitor for the Treatment of Metastatic Melanoma.EBI
Novartis Institutes For Biomedical Research
Synthesis and biological evaluation of di-aryl urea derivatives as c-Kit inhibitors.EBI
Univ. Lille
Investigation of new 2-aryl substituted Benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors targeting vascular endothelial growth factor receptor 2.EBI
Universit£
Discovery of 6-phenylimidazo[2,1-b]thiazole derivatives as a new type of FLT3 inhibitors.EBI
Sichuan University
Discovery of 4-arylamido 3-methyl isoxazole derivatives as novel FMS kinase inhibitors.EBI
Hanyang University
Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells.EBI
Eli Lilly
Synthesis and evaluation of novel 1H-pyrrolo[2,3-b]pyridine-5-carboxamide derivatives as potent and orally efficacious immunomodulators targeting JAK3.EBI
Astellas Pharma
Design, Synthesis, and Structure-Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer.EBI
Sichuan University
Design, synthesis and biological evaluation of novel thieno[3,2-d]pyrimidine derivatives containing diaryl urea moiety as potent antitumor agents.EBI
Shenyang Pharmaceutical University
Design, synthesis and biological evaluation of benzyl 2-(1H-imidazole-1-yl) pyrimidine analogues as selective and potent Raf inhibitors.EBI
Hanyang University
Discovery of a Type III Inhibitor of LIM Kinase 2 That Binds in a DFG-Out Conformation.EBI
Lexicon Pharmaceuticals
Design, synthesis and biological evaluation of novel thieno[3,2-d]pyrimidine derivatives possessing diaryl semicarbazone scaffolds as potent antitumor agents.EBI
Shenyang Pharmaceutical University
Discovery of 4-aryl-N-arylcarbonyl-2-aminothiazoles as Hec1/Nek2 inhibitors. Part I: optimization of in vitro potencies and pharmacokinetic properties.EBI
Development Center For Biotechnology
Design, synthesis and evaluation of novel diaryl urea derivatives as potential antitumor agents.EBI
Peking Union Medical College & Chinese Academy Of Medical Sciences
Optimizing the Physicochemical Properties of Raf/MEK Inhibitors by Nitrogen Scanning.EBI
Chugai Pharmaceutical Co.
Monocarbonyl curcumin analogues: heterocyclic pleiotropic kinase inhibitors that mediate anticancer properties.EBI
Emory University
Discovery and optimization of a novel series of potent mutant B-Raf(V600E) selective kinase inhibitors.EBI
Astrazeneca
Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR).EBI
Exelixis
Structure-activity relationship studies of pyrazolo[3,4-d]pyrimidine derivatives leading to the discovery of a novel multikinase inhibitor that potently inhibits FLT3 and VEGFR2 and evaluation of its activity against acute myeloid leukemia in vitro and in vivo.EBI
Sichuan University
Design and optimization of selective protein kinase C¿ (PKC¿) inhibitors for the treatment of autoimmune diseases.EBI
Vertex Pharmaceuticals
Novel triazolopyridylbenzamides as potent and selective p38a inhibitors.EBI
RhôNe-Poulenc Rorer
Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors: 3. Evaluation of 5-amino-linked thiazolo[5,4-d]pyrimidine and thiazolo[5,4-b]pyridine derivatives.EBI
Takeda Pharmaceutical
Vascular endothelial growth factor (VEGF) receptors: drugs and new inhibitors.EBI
University Of Genoa
Conformation-specific effects of Raf kinase inhibitors.EBI
Takeda California
Life beyond kinases: structure-based discovery of sorafenib as nanomolar antagonist of 5-HT receptors.EBI
National Institute Of Biological Sciences
Discovery of a novel series of potent and orally bioavailable phosphoinositide 3-kinase¿ inhibitors.EBI
Exelixis
Structure-based optimization of aminopyridines as PKC¿ inhibitors.EBI
Vertex Pharmaceuticals
Design, synthesis and antitumor activities of novel bis-aryl ureas derivatives as Raf kinase inhibitors.EBI
Academy Of Military Medical Sciences
Discovery of the novel potent and selective FLT3 inhibitor 1-{5-[7-(3- morpholinopropoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl}-3-p-tolylurea and its anti-acute myeloid leukemia (AML) activities in vitro and in vivo.EBI
Sichuan University
Potent and selective aminopyrimidine-based B-Raf inhibitors with favorable physicochemical and pharmacokinetic properties.EBI
Genentech
Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E.EBI
Ambit Biosciences
Structure based design and syntheses of amino-1H-pyrazole amide derivatives as selective Raf kinase inhibitors in melanoma cells.EBI
Hanyang University
A quantitative analysis of kinase inhibitor selectivity.EBI
Ambit Biosciences
The selectivity of protein kinase inhibitors: a further update.EBI
University Of Dundee
Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme's surface-exposed front region.EBI
Eberhard Karls University Tuebingen
Dual binding site inhibitors of B-RAF kinase.EBI
Johnson & Johnson Pharmaceutical Research & Development
Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors.EBI
Bristol-Myers Squibb Research And Development
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.EBI
University Of Oxford
Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors.EBI
Osi Pharmaceuticals
Pharmacophore identification of Raf-1 kinase inhibitors.EBI
China Pharmaceutical University
Structure-based drug design of a highly potent CDK1,2,4,6 inhibitor with novel macrocyclic quinoxalin-2-one structure.EBI
Banyu Tsukuba Research Institute In Collaboration With Merck Research Laboratories
Design and synthesis of the first generation of novel potent, selective, and in vivo active (benzothiazol-2-yl)acetonitrile inhibitors of the c-Jun N-terminal kinase.EBI
Serono Pharmaceutical Research Institute
Discovery and in vitro evaluation of potent TrkA kinase inhibitors: oxindole and aza-oxindoles.EBI
Glaxosmithkline
Discovery of heterocyclic ureas as a new class of raf kinase inhibitors: identification of a second generation lead by a combinatorial chemistry approach.EBI
Bayer Research Center
The discovery of potent cRaf1 kinase inhibitors.EBI
Glaxo Wellcome
Small molecule inhibitors of BRAF in clinical trials.EBI
The Institute Of Cancer Research
Syntheses of phenylpyrazolodiazepin-7-ones as conformationally rigid analogs of aminopyrazole amide scaffold and their antiproliferative effects on cancer cells.EBI
Hanyang University
1,7-Naphthyridine 1-oxides as novel potent and selective inhibitors of p38 mitogen activated protein kinase.EBI
RhôNe-Poulenc Rorer
Indolin-2-one p38a inhibitors III: bioisosteric amide replacement.EBI
RhôNe-Poulenc Rorer
Comprehensive analysis of kinase inhibitor selectivity.EBI
Ambit Biosciences
9-substituted 6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as highly selective and potent anaplastic lymphoma kinase inhibitors.EBI
Chugai Pharmaceutical Co.
Indolin-2-one p38a inhibitors II: Lead optimisation.EBI
RhôNe-Poulenc Rorer
Exploration of acridine scaffold as a potentially interesting scaffold for discovering novel multi-target VEGFR-2 and Src kinase inhibitors.EBI
Tsinghua University
Discovery of novel tetracyclic compounds as anaplastic lymphoma kinase inhibitors.EBI
Chugai Pharmaceutical Co.
Design and synthesis of 5,6-fused heterocyclic amides as Raf kinase inhibitors.EBI
Novartis Institutes For Biomedical Research
Discovery and optimization of pyrazoline compounds as B-Raf inhibitors.EBI
Millennium Pharmaceuticals
Discovery and structure-activity relationship of 3-aminopyrid-2-ones as potent and selective interleukin-2 inducible T-cell kinase (Itk) inhibitors.EBI
Vertex Pharmaceuticals
Discovery of triazine-benzimidazoles as selective inhibitors of mTOR.EBI
Amgen
Imidazo[1,5-a]pyrazines: orally efficacious inhibitors of mTORC1 and mTORC2.EBI
Osi Pharmaceuticals
Design and synthesis of isoquinolines and benzimidazoles as RAF kinase inhibitors.EBI
Merck Serono
Design and optimization of potent and orally bioavailable tetrahydronaphthalene Raf inhibitors.EBI
Millennium Pharmaceuticals
Indazolylpyrazolopyrimidine as highly potent B-Raf inhibitors with in vivo activity.EBI
Pfizer
Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge region.EBI
Deciphera Pharmaceuticals
Synthesis of aminoquinazoline derivatives and their antiproliferative activities against melanoma cell line.EBI
Institute Of Science And Technology
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).EBI
Ambit Biosciences
Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.EBI
Center For Molecular Medicine Of The Austrian Academy Of Sciences
New approaches to molecular cancer therapeutics.EBI
The Institute Of Cancer Research
Rational design of inhibitors that bind to inactive kinase conformations.EBI
Novartis Research Foundation
1,4-dihydropyrazolo[4,3-d]imidazole phenyl derivatives: a novel type II Raf kinase inhibitors.EBI
Institute Of Science And Technology
Discovery and evaluation of 7-alkyl-1,5-bis-aryl-pyrazolopyridinones as highly potent, selective, and orally efficacious inhibitors of p38alpha mitogen-activated protein kinase.EBI
Amgen
Selectively nonselective kinase inhibition: striking the right balance.EBI
Schering-Plough
Non-hinge-binding pyrazolo[1,5-a]pyrimidines as potent B-Raf kinase inhibitors.EBI
Wyeth Research
BRAF inhibitors based on an imidazo[4,5]pyridin-2-one scaffold and a meta substituted middle ring.EBI
The Institute Of Cancer Research
Discovery of a novel Her-1/Her-2 dual tyrosine kinase inhibitor for the treatment of Her-1 selective inhibitor-resistant non-small cell lung cancer.EBI
Hanmi Research Center
Discovery and characterization of the N-phenyl-N'-naphthylurea class of p38 kinase inhibitors.EBI
Boehringer Ingelheim Pharmaceuticals
From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells.EBI
University Of Illinois At Chicago
Virtual screening for Raf-1 kinase inhibitors based on pharmacophore model of substituted ureas.EBI
China Pharmaceutical University
The identification of pyrazolo[1,5-a]pyridines as potent p38 kinase inhibitors.EBI
Glaxosmithkline
Novel N9-arenethenyl purines as potent dual Src/Abl tyrosine kinase inhibitors.EBI
Ariad Pharmaceuticals
Biphenyl amide p38 kinase inhibitors 4: DFG-in and DFG-out binding modes.EBI
Glaxosmithkline
Pharmacologic inhibition of tpl2 blocks inflammatory responses in primary human monocytes, synoviocytes, and blood.EBI
Wyeth Research
New modifications to the area of pyrazole-naphthyl urea based p38 MAP kinase inhibitors that bind to the adenine/ATP site.EBI
Boehringer Ingelheim Pharmaceuticals
Discovery and preliminary structure-activity relationship studies of novel benzotriazine based compounds as Src inhibitors.EBI
Targegen
Aza-stilbenes as potent and selective c-RAF inhibitors.EBI
Glaxosmithkline
Discovery of 2-pyrimidyl-5-amidothiophenes as potent inhibitors for AKT: synthesis and SAR studies.EBI
Chiron
High-Throughput Screening Platform in Postnatal Heart Cells and Chemical Probe Toolbox to Assess Cardiomyocyte Proliferation.EBI
Christian-Albrechts University Of Kiel
Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development.EBI
University Of Arkansas For Medical Sciences
Discovery of novel spiro compound as RAF kinase inhibitor with in vitro potency against KRAS mutant cancer.EBI
Eternity Bioscience
Therapeutic Potential and Activity Modulation of the Protein Lysine Deacylase Sirtuin 5.EBI
Sapienza University Of Rome
Application of Rapidly Accelerating Fibrosarcoma Protein Degraders in Drug Discovery.EBI
Usona Institute
Rapid computational identification of the targets of protein kinase inhibitors.EBI
University Of Iowa
Discovery of CH7057288 as an Orally Bioavailable, Selective, and Potent pan-TRK Inhibitor.EBI
Chugai Pharmaceutical Co.
Design and synthesis of new quinoline derivatives as selective C-RAF kinase inhibitors with potent anticancer activity.EBI
University Of Sharjah
The overview of Mitogen-activated extracellular signal-regulated kinase (MEK)-based dual inhibitor in the treatment of cancers.EBI
Zhengzhou University
Evaluation of imidazo[2,1-b]thiazole-based anticancer agents in one decade (2011-2020): Current status and future prospects.EBI
University Of Sharjah
Discovery of New Imidazo[2,1-EBI
National Research Centre (Nrc)
A novel series of p38 MAP kinase inhibitors for the potential treatment of rheumatoid arthritis.EBI
Astrazeneca
Discovery of spiro amide SHR902275: A potent, selective, and efficacious RAF inhibitor targeting RAS mutant cancers.EBI
Eternity Bioscience
Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis.EBI
Novartis Institutes For Biomedical Research
Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a 5-Fluoro-4-(3EBI
Genentech
Discovery of first-in-class imidazothiazole-based potent and selective ErbB4 (HER4) kinase inhibitors.EBI
Korea Institute Of Science And Technology
Omega-carboxypyridyl substituted ureas as Raf kinase inhibitors: SAR of the amide substituent.EBI
Bayer Research Center
Structural optimization and structure-activity relationship studies of N-phenyl-7,8-dihydro-6H-pyrimido[5,4-b][1,4]oxazin-4-amine derivatives as a new class of inhibitors of RET and its drug resistance mutants.EBI
Sichuan University/Collaborative Innovation Center Of Biotherapy
From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as Agents for the Treatment of Triple Negative Breast Cancer.EBI
Sichuan University
Identification of methyl (5-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinopyrrolo[2,1-f][1,2,4]triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)carbamate (CYH33) as an orally bioavailable, highly potent, PI3K alpha inhibitor for the treatment of advanced solid tumors.EBI
Chinese Academy Of Sciences
Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a Pyridopyridazinone pan-RAF Kinase Inhibitor.EBI
Genentech
2-Anilinoquinoline based arylamides as broad spectrum anticancer agents with B-RAFEBI
Korea Institute Of Science And Technology (Kist)
Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate.EBI
Boehringer Ingelheim Pharmaceuticals
Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor.EBI
Merck Research Laboratories
Pyrimidinylimidazole inhibitors of p38: cyclic N-1 imidazole substituents enhance p38 kinase inhibition and oral activity.EBI
Glaxosmithkline
Anticancer profile of newly synthesized BRAF inhibitors possess 5-(pyrimidin-4-yl)imidazo[2,1-b]thiazole scaffold.EBI
National Research Centre (Nrc)
Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2.EBI
Research Biomet. Glaxo Wellcome Medicines Research Centre
Synthesis and structure-activity relationships of 3-cyano-4-(phenoxyanilino)quinolines as MEK (MAPKK) inhibitors.EBI
Wyeth-Ayerst Research
Discovery and optimization of heteroaryl piperazines as potent and selective PI3K? inhibitors.EBI
Merck
Optimization of microtubule affinity regulating kinase (MARK) inhibitors with improved physical properties.EBI
Merck And
Optimization of an azetidine series as inhibitors of colony stimulating factor-1 receptor (CSF-1R) Type II to lead to the clinical candidate JTE-952.EBI
Japan Tobacco
Urea Derivatives in Modern Drug Discovery and Medicinal Chemistry.EBI
Purdue University
Novel potent substituted 4-amino-2-thiopyrimidines as dual VEGFR-2 and BRAF kinase inhibitors.EBI
National Research Centre
Estrogen signaling: An emanating therapeutic target for breast cancer treatment.EBI
Indian Institute Of Technology (Bhu)
Discovery of novel phenoxybenzamide analogues as Raf/HDAC dual inhibitors.EBI
China Pharmaceutical University
Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase.EBI
Merck Research Laboratories
Discovery of 4EBI
TBA
Synthesis and evaluation of thieno[3,2-d]pyrimidine derivatives as novel FMS inhibitors.EBI
Chung-Ang University
Pyrroles and other heterocycles as inhibitors of p38 kinase.EBI
Merck Research Laboratory
Targeting tropomyosin receptor kinase for cancer therapy.EBI
China Pharmaceutical University
Design and Discovery of EBI
Novartis Institutes For Biomedical Research
Design, synthesis, and in vitro evaluation of N-(3-(3-alkyl-1H-pyrazol-5-yl) phenyl)-aryl amide for selective RAF inhibition.EBI
Hanyang University
Discovery of potent Pan-Raf inhibitors with increased solubility to overcome drug resistance.EBI
China Pharmaceutical University
ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.EBI
University Of Florida
Discovery of a potent p38?/MAPK14 kinase inhibitor: Synthesis, inávitro/inávivo biological evaluation, and docking studies.EBI
University Of Sharjah
Design and synthesis of new potent anticancer benzothiazole amides and ureas featuring pyridylamide moiety and possessing dual B-Raf(V600E) and C-Raf kinase inhibitory activities.EBI
Korea Institute Of Science And Technology (Kist)
Discovery of 6-(2-(dimethylamino)ethyl)-N-(5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole-6-yl)pyrimidin-2-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-amine as a highly potent cyclin-dependent kinase 4/6 inhibitor for treatment of cancer.EBI
Shanghai Pharmaceuticals Holding
Fluorine Scanning by Nonselective Fluorination: Enhancing Raf/MEK Inhibition while Keeping Physicochemical Properties.EBI
Chugai Pharmaceutical Co.
Solution phase parallel synthesis and evaluation of MAPK inhibitory activities of close structural analogues of a Ras pathway modulator.EBI
Morphochem
Recent advances of RAF (rapidly accelerated fibrosarcoma) inhibitors as anti-cancer agents.EBI
University Of Science & Technology (Ust)
Design and biological evaluation of novel triaryl pyrazoline derivatives with dioxane moiety for selective BRAFEBI
Nanjing University
Novel Quinazolinone Inhibitors of ALK2 Flip between Alternate Binding Modes: Structure-Activity Relationship, Structural Characterization, Kinase Profiling, and Cellular Proof of Concept.EBI
Institute Of Cancer Research
ROCK inhibitors 3: Design, synthesis and structure-activity relationships of 7-azaindole-based Rho kinase (ROCK) inhibitors.EBI
Vertex Pharmaceuticals
ROCK inhibitors 2. Improving potency, selectivity and solubility through the application of rationally designed solubilizing groups.EBI
Vertex Pharmaceuticals
New insights in the structure-activity relationships of 2-phenylamino-substituted benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors.EBI
Universit£
Cyclin-Dependent Kinase 8: A New Hope in Targeted Cancer Therapy?EBI
University Of South Australia
Current Insights of BRAF Inhibitors in Cancer.EBI
Albert Einstein College Of Medicine
Design, synthesis and antitumor activity of Novel Sorafenib derivatives bearing pyrazole scaffold.EBI
Jiangxi Science & Technology Normal University
Design, synthesis, biological evaluation and molecular modeling of novel 1H-pyrazolo[3,4-d]pyrimidine derivatives as BRAFEBI
Southern Medical University
Design, synthesis and evaluation of derivatives based on pyrimidine scaffold as potent Pan-Raf inhibitors to overcome resistance.EBI
China Pharmaceutical University
Steady-state kinetic mechanism of Ras farnesyl:protein transferase.BDB
Merck Research Laboratories
Pharmacological characterization of (E)-N-(4-fluorobut-2-enyl)-2beta-carbomethoxy-3beta-(4'-tolyl)nortropane (LBT-999) as a highly promising fluorinated ligand for the dopamine transporter.BDB
University Of Tours
Alpha-1 adrenergic receptor binding in aortas from rat and dog: comparison of [3H]prazosin and beta-iodo-[125I]-4-hydroxyphenyl-ethyl-aminomethyl-tetralone.BDB
Unwersity Of Misscuri
Human liver glycogen phosphorylase inhibitors bind at a new allosteric site.BDB
Pfizer
Development of a highly water-soluble peptide-based human neutrophil elastase inhibitor; AE-3763 for treatment of acute organ injury.BDB
Dainippon Sumitomo Pharma
Novel cambinol analogs as sirtuin inhibitors: synthesis, biological evaluation, and rationalization of activity.BDB
University Of St. Andrews
Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity.BDB
Pfizer
Flexible cyclic ethers/polyethers as novel P2-ligands for HIV-1 protease inhibitors: design, synthesis, biological evaluation, and protein-ligand X-ray studies.BDB
Purdue University
4,1-Benzoxazepinone analogues of efavirenz (Sustiva) as HIV-1 reverse transcriptase inhibitors.BDB
Dupont Pharmaceuticals
Dihydro(alkylthio)(naphthylmethyl)oxopyrimidines: novel non-nucleoside reverse transcriptase inhibitors of the S-DABO series.BDB
Sapienza University Of Rome
Aza-peptide analogs as potent human immunodeficiency virus type-1 protease inhibitors with oral bioavailability.BDB
Ciba-Geigy